136
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Role of pharmacists in adherence in oncology patients

, , , , &
Article: 2359000 | Received 05 Apr 2024, Accepted 20 May 2024, Published online: 28 May 2024
 

Abstract

Adherence is the degree to which the patient’s behaviour and actions correspond to the physician’s established treatment regimen regarding timing, dose and frequency. Patient counselling by both oncologists and pharmacists and optimization of the therapeutic regimen can critically impact decision-making and adherence to therapy. We performed a two-step study to identify factors influencing adherence to therapy from the perspective of oncology hospital pharmacists in Bulgaria. The results show that the major factors affecting anticancer therapy adherence are the manifestation of adverse drug reactions and distrust in therapy. These could be overcome with improved communication between patients, oncologists and pharmacists on therapy aspects and more active involvement of the hospital pharmacists in therapy monitoring with a main focus on identifying possible drug-related problems based on safety profile, drug-drug interactions and non-adherence.

Acknowledgements

SK and GP developed the questionnaire and conducted the online survey. NR performed the literature review. MD and ZM wrote the methodology and contributed to analysing and writing. JA contributed to writing and validating the data results. All authors contributed to the article and approved the submitted version.

Disclosure statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare no conflict of interest.

Data availability statement

The data that support the findings reported in this study are available from the corresponding author [MD] upon reasonable request.

Additional information

Funding

This study received funding from the Science Fund, Project 739/25.02.2022, Evaluation of the compliance and adherence to therapy in case of socially important diseases with a high degree of non-adherence. Contract KP-06-COST/6 from 14 June 2022.